Pancreatic cancer drug wins FDA approval, marking shift toward targeted therapy
The Food and Drug Administration has approved a therapy for advanced pancreatic cancer that extends survival and is the first to target a specific genetic driver of the disease. The approval signals a new direction in treating this aggressive cancer.
Related stories
FDA clears Revolution Medicines' daraxonrasib for pancreatic cancer · Cancer research
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “STAT+: FDA approves new pancreatic cancer drug expected to usher in new era of treatment.” Browse more stories.